SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.89-0.6%2:11 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (7356)11/18/2002 10:35:55 PM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
Vol. 303, Issue 3, 1007-1013, December 2002

C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion
Terrance D. Barrett, James K. Hennan, Rory M. Marks and Benedict R. Lucchesi

University of Michigan Medical School, Departments of Pharmacology (T.D.B., J.K.H., B.R.L.) and Internal Medicine (R.M.M.), Ann Arbor, Michigan

C-Reactive protein (CRP), a marker for acute inflammation, is associated with increased risk of cardiovascular events. The mechanism underlying this association is uncertain. An acute inflammatory response was induced in rabbits by subcutaneous injection of croton oil (CO) 1 to 3 days before 30 min of regional myocardial ischemia/180 min of reperfusion. CO treatment increased plasma CRP from below the limit of detection to 2.5 ± 0.5 mg/dl and was associated with an increase in infarct size expressed as percentage of risk region [32 ± 6% vehicle controls (n = 7) to 47 ± 9% CO-treated rabbits (n = 7; P < 0.05]. After 10 min of ischemia and 180 min reperfusion, no infarct was found in controls; however, an infarct of 7 ± 1% was found in CO-treated rabbits (P < 0.05; CRP, 2.3 ± 0.4 mg/dl). The CRP-related increase in infarct size was not observed in croton oil-treated, C6-deficient rabbits (n = 5/group), indicating the involvement of complement. In these rabbits, infarct size was 22 ± 2% (P < 0.05) despite having plasma CRP of 4.3 ± 0.4 mg/dl. The CRP-associated increase in infarct size was ameliorated by pretreatment with heparin (n = 7; infarct size 33 ± 3%; CRP, 2.3 ± 0.3 mg/dl; P < 0.05) or N-acetylheparin (n = 7; infarct size 23 ± 4%; CRP, 3.1 ± 0.5 mg/dl; P < 0.05). These observations may explain why increased serum CRP is associated with an augmented risk for cardiovascular events.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext